SLC6A3 is a risk factor for Parkinson's disease: A meta-analysis of sixteen years' studies

Neuroscience Letters

Volumn 564, Issue , 2014, Pages 99-104

  Zhai, Desheng ^a   Li, Songji ^a   Zhao, Ying ^a,b   Lin, Zhicheng ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Dopamine transporter; Genetic etiology; Neurodegeneration; Parkinson's disease; Polymorphism

Indexed keywords

DOPAMINE TRANSPORTER; SLC6A3 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ALLELE; ARTICLE; ASIAN; CASE CONTROL STUDY; CAUCASIAN; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; META ANALYSIS; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; FEMALE; GENETICS; MALE;

DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; PARKINSON DISEASE; RISK FACTORS;

EID: 84895738156     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.10.060     Document Type: Article

References (49)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991, 337:1321-1324.
2. Carlquist J.F., Menlove R.L., Murray M.B., O'Connell J.B., Anderson J.L. HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy, Validation study and meta-analysis of published HLA association studies. Circulation 1991, 83:515-522.
3. Brown A.J., Roberts D.C. The effect of fasting triacylglyceride concentration and apolipoprotein E polymorphism on postprandial lipemia. Arterioscler. Thromb. Vasc. Biol. 1991, 11:1737-1744.
4. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
5. De Palma G., Dick F.D., Calzetti S., Scott N.W., Prescott G.J., Osborne A., Haites N., Mozzoni P., Negrotti A., Scaglioni A., Mutti A. A case-control study of Parkinson's disease and tobacco use: gene-tobacco interactions. Mov. Disord. 2010, 25:912-919.
6. de Rijk M.C., Breteler M.M., Graveland G.A., Ott A., Grobbee D.E., van der Meche F.G., Hofman A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995, 45:2143-2146.
7. Dick F.D., De Palma G., Ahmadi A., Osborne A., Scott N.W., Prescott G.J., Bennett J., Semple S., Dick S., Mozzoni P., Haites N., Wettinger S.B., Mutti A., Otelea M., Seaton A., Soderkvist P., Felice A. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup. Environ. Med. 2007, 64:673-680.
8. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
9. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39:175-191.
10. Fazeli G., Oli R.G., Schupp N., Stopper H. The role of the dopamine transporter in dopamine-induced DNA damage. Brain Pathol. 2011, 21:237-248.
11. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 1993, 14:43-49.
12. Glass G.V. Primary, secondary, and meta-analysis of research. Educational Researcher 1976, 5:3-8.
13. Goudreau J.L., Maraganore D.M., Farrer M.J., Lesnick T.G., Singleton A.B., Bower J.H., Hardy J.A., Rocca W.A. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. Mov. Disord. 2002, 17:1305-1311.
14. Greenwood T.A., Schork N.J., Eskin E., Kelsoe J.R. Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol. Psychiatry 2006, 11:125-133. 115.
15. Jeng W., Ramkissoon A., Wells P.G. Reduced DNA oxidation in aged prostaglandin H synthase-1 knockout mice. Free Radic. Biol. Med. 2011, 50:550-556.
16. Juyal R.C., Das M., Punia S., Behari M., Nainwal G., Singh S., Swaminath P.V., Govindappa S.T., Jayaram S., Muthane U.B., Thelma B.K. Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker. Neurogenetics 2006, 7:223-229.
17. Kang A.M., Palmatier M.A., Kidd K.K. Global variation of a 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene (SLC6A3). Biol. Psychiatry 1999, 46:151-160.
18. Kelada S.N., Costa-Mallen P., Checkoway H., Carlson C.S., Weller T.S., Swanson P.D., Franklin G.M., Longstreth W.T., Afsharinejad Z., Costa L.G. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenet Genomics 2005, 15:659-668.
19. Kim J.W., Kim D.H., Kim S.H., Cha J.K. Association of the dopamine transporter gene with Parkinson's disease in Korean patients. J. Korean Med. Sci. 2000, 15:449-451.
20. Kimura M., Matsushita S., Arai H., Takeda A., Higuchi S. No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease. Ann. Neurol. 2001, 49:276-277.
21. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
22. Le Couteur D.G., Leighton P.W., McCann S.J., Pond S. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov. Disord. 1997, 12:760-763.
23. Leighton P.W., Le Couteur D.G., Pang C.C., McCann S.J., Chan D., Law L.K., Kay R., Pond S.M., Woo J. The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology 1997, 49:1577-1579.
24. Lin C.N., Liu H.C., Tsai S.J., Liu T.Y., Hong C.J. Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G). Eur. Neurol. 2002, 48:207-209.
25. Lin J.J., Yueh K.C., Chang D.C., Chang C.Y., Yeh Y.H., Lin S.Z. The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients. J. Neurol. Sci. 2003, 209:87-92.
26. Lynch D.R., Mozley P.D., Sokol S., Maas N.M., Balcer L.J., Siderowf A.D. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov. Disord. 2003, 18:804-812.
27. Mercier G., Turpin J.C., Lucotte G. Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: no association found. J. Neurol. 1999, 246:45-47.
28. Migliore L., Coppede F. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat. Res. 2009, 674:73-84.
29. Mitchell R.J., Howlett S., Earl L., White N.G., McComb J., Schanfield M.S., Briceno I., Papiha S.S., Osipova L., Livshits G., Leonard W.R., Crawford M.H. Distribution of the 3'VNTR polymorphism in the human dopamine transporter gene in world populations. Hum. Biol. 2000, 72:295-304.
30. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 2005, 28:57-87.
31. Morino H., Kawarai T., Izumi Y., Kazuta T., Oda M., Komure O., Udaka F., Kameyama M., Nakamura S., Kawakami H. A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. Ann. Neurol. 2000, 47:528-531.
32. Muangpaisan W., Hori H., Brayne C. Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J. Epidemiol. 2009, 19:281-293.
33. Nicholl D.J., Bennett P., Hiller L., Bonifati V., Vanacore N., Fabbrini G., Marconi R., Colosimo C., Lamberti P., Stocchi F., Bonuccelli U., Vieregge P., Ramsden D.B., Meco G., Williams A.C. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders, European Stud Group on Atypical Parkinsonism. Neurology 1999, 53:1415-1421.
34. Nishimura M., Kaji R., Ohta M., Mizuta I., Kuno S. Association between dopamine transporter gene polymorphism and susceptibility to Parkinson's disease in Japan. Mov. Disord. 2002, 17:831-832.
35. Pankratz N., Wilk J.B., Latourelle J.C., DeStefano A.L., Halter C., Pugh E.W., Doheny K.F., Gusella J.F., Nichols W.C., Foroud T., Myers R.H. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 2009, 124:593-605.
36. Plante-Bordeneuve V., Taussig D., Thomas F., Said G., Wood N.W., Marsden C.D., Harding A.E. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 1997, 48:1589-1593.
37. Ramkissoon A., Wells P.G. Human prostaglandin H synthase (hPHS)-1- and hPHS-2-dependent bioactivation, oxidative macromolecular damage, and cytotoxicity of dopamine, its precursor, and its metabolites. Free Radic. Biol. Med. 2011, 50:295-304.
38. Ritz B.R., Manthripragada A.D., Costello S., Lincoln S.J., Farrer M.J., Cockburn M., Bronstein J. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ. Health Perspect. 2009, 117:964-969.
39. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
40. Singh M., Khan A.J., Shah P.P., Shukla R., Khanna V.K., Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol. Cell. Biochem. 2008, 312:131-138.
41. Spencer W.A., Jeyabalan J., Kichambre S., Gupta R.C. Oxidatively generated DNA damage after Cu(II) catalysis of dopamine and related catecholamine neurotransmitters and neurotoxins: role of reactive oxygen species. Free Radic. Biol. Med. 2011, 50:139-147.
42. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 1999, 55:659-665.
43. Uhl G.R. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov. Disord. 2003, 18(Suppl. 7):S71-S80.
44. Uhl G.R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann. Neurol. 1998, 43:555-560.
45. van de Giessen E., de Win M.M., Tanck M.W., van den Brink W., Baas F., Booij J. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J. Nucl. Med. 2009, 50:45-52.
46. Wang Association between genetic polymorphism of dopamine transporter gene and susceptibility to Parkinson's disease. Natl. Med. J. China 2000, 80:346-348.
47. Xu M., Lin Z. Genetic influences of dopamine transport gene on alcohol dependence: a combined analysis of 13 studies with 2483 cases and 1753 controls. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1255-1260.
48. Zhang Assoc iation between dopam ine tran sporter gene polymorphism and Parkinson's disease. Chin. J. Med. Genet. 2001, 18:431-434.
49. Zhao Parkinson's disease sensitivity and the 402bp VNTR polymorphism of DAT gene. Chin. J. Geriatr. 2004, 23:457-459.